title: [From BNP to ST2: Which biomarkers to use in practice?]
abstract: The management of heart failure requires reproducible and easily accessible biomarkers. For diagnosis, measurement of natriuretic peptides is highly recommended as first line. For the stratification of patients, natriuretic peptide testing is highly recommended and other biomarkers such as troponin or fibrosis markers can also be used. For any biomarkers, changes in blood levels over time is more relevant than a single assay. For monitoring as well as guiding heart failure treatment, serial testing of natriuretic peptides is useful in young patients with systolic dysfunction. For the screening of high-risk patients, natriuretic peptides testing is not fully validated yet.
authors.affiliation: Assistance publique-Hôpitaux de Paris, université Paris Diderot, groupe hospitalier Lariboisière Saint-Louis, Inserm U942, 75010 Paris, France. Electronic address: damien.logeart@aphp.fr.
authors.forename: Damien
authors.initials: D
authors.lastname: Logeart
authors.affiliation: Assistance publique-Hôpitaux de Paris, université Paris Diderot, groupe hospitalier Lariboisière Saint-Louis, Inserm U942, 75010 Paris, France.
authors.forename: Mathilde
authors.initials: M
authors.lastname: Baudet
mesh_terms: D015415:Biomarkers / Q000097:blood; D006333:Heart Failure / Q000097:blood* / Q000175:diagnosis*; D006801:Humans; D000072179:Interleukin-1 Receptor-Like 1 Protein / Q000097:blood*; D020097:Natriuretic Peptide, Brain / Q000097:blood*
chemical_list: D015415:Biomarkers; C079241:IL1RL1 protein, human; D000072179:Interleukin-1 Receptor-Like 1 Protein; D020097:Natriuretic Peptide, Brain